IV ubidecarenone: Phase II started

Berg began an open-label, U.S. Phase II trial to evaluate IV BPM 31510 at a starting dose of 110 mg/kg given over 144 hours every week plus gemcitabine in up to 25 patients. The first cycle is 6 weeks...